

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)		Complete if Known						
		Application Number	10/505,244					
		Filing Date	January 18, 2005					
		First Named Inventor	Kuwada					
		Group Art Unit	1614					
Examiner Name	Pagonakis, Anna							
U.S. PATENT DOCUMENTS								
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
FOREIGN PATENT DOCUMENTS								
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No			
NON-PATENT DOCUMENTS								
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)						
/A.P./	C4	Hu <i>et al.</i> , "An IκBα Inhibitor Causes Leukemia Cell Death through a p38 MAP Kinase-dependent, NF-κB-Independent Mechanism," <i>Cancer Res</i> 61:6290-6296, 2001						
/A.P./	C2	Cory <i>et al.</i> , "Implications of the Involvement of the Endoplasmic Reticulum Stress Pathway in Drug-Induced Apoptosis," <i>Anticancer Res</i> 28(2A):681-686, 2008						
/A.P./	C3	Vega <i>et al.</i> , "Rituximab-Induced Inhibition of YY1 and Bcl-x _L Expression in Ramos Non-Hodgkin's Lymphoma Cell Line via Inhibition of NF-κB Activity: Role of YY1 and Bcl-x _L in Fas Resistance and Chemoresistance, Respectively," <i>J Immunol</i> 175:2174-2183, 2005						
/A.P./	C4	Huerta-Yepez <i>et al.</i> , "Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediates apoptosis via inactivation of NF-κB and inhibition of Bcl-x _L expression," <i>Oncogene</i> 23:4993-5003, 2004						
/A.P./	C5	Mabuchi <i>et al.</i> , "Inhibition of NF-κB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models," <i>J Biol Chem</i> 279:23477-23485, 2004						
/A.P./	C6	El-Rayes <i>et al.</i> , "Phase II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer," <i>Cancer Chemother Pharmacol</i> 61:283-289, 2008						
/A.P./	C7	Becerra <i>et al.</i> , "Increased Toxicity and Lack of Efficacy of Rofecoxib in Combination with Chemotherapy for Treatment of Metastatic Colorectal Cancer: A Phase II Study," <i>Int J Cancer</i> 105:868-872, 2003						
Examiner Signature:		/Anna Pagonakis/		Date Considered:				
				11/26/2008				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								